A Phase 1/2 interventional study of BGB-11417 and Azacitidine in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasm, sponsored by BeOne Medicines. Recruiting at 47 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by BeOne Medicines · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 37th largest by planned enrollment of the 433 interventional ones that give a count, is one of 44 that started in 2021, is one of 66 in phase 1/2, reaches primary completion later than 248 of the 288 other live ones, and was the 128th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18+
iCell Gene Therapeutics · Sites in China
Ages 18–70
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
473 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 187 · Phase 2 191 · Phase 3 77 · Phase 4 13
First in 2003; this study’s year is marked. 44 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 433 interventional studies, 100 across the 39 observational. Of the 72 that completed or were terminated, 9 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 473 have an industry lead sponsor. The 10 most frequent:
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
BeOne Medicines has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
71 of the studies in Leukemia, Myeloid, Acute with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07712848Phase 3The Second Affiliated Hospital of Kunming Medical UniversityDEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | 2026-12-01 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT06990321Phase 3Yehui TanEffectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | 2026-12-31 |
| NCT06345365Phase 3Zhongnan HospitalMA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | 2026-12-31 |
Add all 71 to your calendar (.ics) → With an account.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Key Inclusion Criteria:
Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
Adequate organ function defined as:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
Drug: BGB-11417 · Drug: Azacitidine
Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
Drug: Azacitidine · Drug: BGB-11417
Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
Drug: BGB-11417 · Drug: Azacitidine · Drug: Posaconazole
Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
Drug: BGB-11417
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Also known as: Sonrotoclax
Intravenous or subcutaneous administration for 7 days.
Oral administration for 8 days on second cycle only.
Oral administration for 28 days on a 28-day cycle.
Oral administration for 10, 14 or 21 days on a 28-day
Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time frame: Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)
Part 1 And 2: Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: Approximately 24 months
Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate
CR plus CRh will be defined as the percentage of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
Time frame: Approximately 24 months
Part 3 MDS Cohort: Modified Overall Response (mOR) Rate
The mOR will be defined as the percentage of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).
Time frame: Approximately 24 months
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable timepoint (t) (AUC0-t) Of BGB-11417 When Administered Alone and when Co-administered With Posaconazole
Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Administered Alone and When Co-administered With Posaconazole
Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Administered Alone and When Co-administered With Posaconazole
Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs
Time frame: Cycle 2
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs
Time frame: Approximately 24 months
Parts 1 And 2 AML Cohort: Complete remission (CR) + Morphologic CR With Partial Hematologic Recovery (CRh)
Time frame: Approximately 24 months
Parts 1 And 2 MDS Cohort: mOR Rate
Time frame: Approximately 24 months
Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: Terminal Half-life (t1/2) Of Azacitidine When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: Apparent Total Clearance Of Azacitidine From Plasma (CL/F) When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417
Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine
Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine
Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine
Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine
Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Part 3: Number Of Participants Experiencing TEAEs
Time frame: Approximately 24 months
Part 3: Complete Response Rate
CR will be defined as the percentage of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
Time frame: Approximately 24 months
Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate
CRi will be defined as the percentage of participants whose BOR is CRi.
Time frame: Approximately 24 months
Part 3 AML Cohort: Overall Response Rate (ORR)
The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.
Time frame: Approximately 24 months
Part 3 AML Cohort: Duration Of Response (DOR)
DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.
Time frame: Approximately 24 months
Part 3 AML Cohort: Time To Response (TTR)
TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.
Time frame: Approximately 24 months
Part 3 Event-free Survival (EFS)
EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.
Time frame: Approximately 24 months
Part 3 Overall Survival (OS)
OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.
Time frame: Approximately 24 months
Part 3 AML Cohort: Number of Participants with Transfusion Independence
Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
Time frame: Approximately 24 months
Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E)
The proportion of participants whose BOR is HI-E
Time frame: Approximately 24 months
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P)
The proportion of participants whose BOR is HI-P
Time frame: Approximately 24 months
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N)
The proportion of participants whose BOR is HI-N will be reported.
Time frame: Approximately 24 months
Part 3 MDS Cohort: Number of participants with Transfusion Independence
Transfusion independence will be defined as the percentage of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
Time frame: Approximately 24 months
Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine
Time frame: Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose)
Part 3 MDS cohort: Partial Hematologic Recovery CRh
Percentage of participants with partial hematologic recovery will be reported
Time frame: Approximately 24 months
Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery
Percentage of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported.
Time frame: Approximately 24 months
Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417
Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)
Part 3 MDS (Treated with Monotherapy): Modified Overall Response
Percentage of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR)
Time frame: Approximately 24 months
Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417
Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Aug 2028, 87 months after the start.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 87 months is above that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonrotoclax